Previous Close | 3.8000 |
Open | 3.7300 |
Bid | 3.5600 x 4000 |
Ask | 3.8000 x 4000 |
Day's Range | 3.6700 - 3.8400 |
52 Week Range | 3.0200 - 19.3700 |
Volume | |
Avg. Volume | 4,025,850 |
Market Cap | 692.089M |
Beta (5Y Monthly) | 1.27 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.7230 |
Earnings Date | Feb 23, 2022 - Feb 28, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 5.95 |
Nektar Therapeutics (Nasdaq: NKTR) today announced the promotion of Jillian B. Thomsen to Senior Vice President (SVP) & Chief Financial Officer. Ms. Thomsen has served as SVP, Finance & Chief Accounting Officer of Nektar since 2008, and is a key member of our Executive Committee. Gil Labrucherie, the company's current Chief Operating Officer & Chief Financial Officer, will be departing the company to pursue another opportunity at a private biotechnology company.
An investment climate that's suddenly turned chilly may leave promising companies out in the cold.
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...